Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abeona Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed commercial-stage biopharmaceutical company with common stock traded as ABEO. Recent Form 8-K reports cover operating results, ZEVASKYN commercial launch disclosures, completion of the sale of a Rare Pediatric Disease Priority Review Voucher received after FDA approval of ZEVASKYN, and other material events.
Proxy and governance filings describe annual meeting procedures, board composition, committee assignments, director independence, compensation matters, and amendments to the company’s bylaws. Those bylaws disclosures address stockholder meeting mechanics, virtual meetings, proposal and nomination procedures, quorum requirements, and other Delaware corporate governance provisions.
Abeona Therapeutics Inc. insider data show that Keith A. Goldan is a reporting person serving as a director. The Form 3 insider filing excerpt lists no buy, sell, acquisition, or disposition transactions and shows no derivative positions or holding entries in the provided data.
Abeona Therapeutics Inc. reported that its Board of Directors expanded from nine to ten members and appointed Keith A. Goldan as a Class 1 independent director, effective April 1, 2026, with a term expiring at the 2026 annual stockholders’ meeting. He was also named Chair of the Audit Committee, and the Board determined he meets Nasdaq independence standards. Abeona will pay him an annual cash Board fee of $50,000 and a one-time $150,000 restricted stock award that vests over one year, with eligibility for the Board’s next regular equity grant in 2027.
Abeona Therapeutics ownership disclosure: Funicular Funds, LP, Cable Car Capital, LP and Jacob Ma-Weaver each report beneficial ownership of 3,007,329 shares of Abeona Therapeutics common stock, representing 5.3% of the class. The calculation references 57,049,023 shares outstanding as of March 17, 2026. The filings list sole voting and sole dispositive power over the reported shares and provide the filers' business address in San Francisco.
Abeona Therapeutics Inc. CEO Vishwas Seshadri sold 29,985 shares of common stock in an open-market transaction. The sale occurred on March 31, 2026 at a weighted average price of $4.3849 per share, with individual trades between $4.31 and $4.43.
After the transaction, Seshadri directly held 1,430,423 shares of Abeona common stock. The filing states that the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on September 17, 2024, indicating it was scheduled in advance.
ABEO filed a Form 144 notifying a proposed sale of 29,985 shares of Common Stock. The filing identifies these shares as Restricted Stock dated 06/05/2024 and notes a prior sale of 69,832 shares on 01/22/2026 for $372,267.00.
The notice lists the broker Stifel Nicolaus & Company Inc and indicates Nasdaq as the exchange; timing and proceeds distribution beyond the amounts shown are not detailed in the excerpt.
Abeona Therapeutics Inc. ownership filing reports that Daniel Kaufman beneficially owns 2,943,629 shares of Common Stock, representing 5.16% of the class. The filing lists Kaufman’s sole voting and dispositive power over these shares.
The Schedule 13G is signed by Daniel Kaufman on 03/27/2026 and discloses his address and CUSIP 00289Y206.
Abeona Therapeutics Inc ownership update: The Vanguard Group filed an amendment reporting zero shares beneficially owned of Abeona common stock following an internal realignment. The filing states Vanguard's subsidiaries will report separately in reliance on SEC Release No. 34-39538, and Vanguard no longer is deemed to beneficially own the securities reported by those subsidiaries.
Abeona Therapeutics Inc. reported that its Board approved Third Amended and Restated Bylaws, effective March 16, 2026, fully replacing bylaws adopted in July 2024. The revisions clarify how annual and special shareholder meetings can be called, postponed, rescheduled, or canceled, and expressly allow virtual meetings under Delaware law.
The bylaws eliminate the requirement to make a shareholder list available at meetings, add rules for attending meetings via remote communication, and raise the quorum requirement from one-third to 50% of shares entitled to vote. They also strengthen procedural and disclosure requirements for shareholder proposals and director nominations, including conditions for using the SEC’s universal proxy rules.
Abeona Therapeutics Inc. is now a commercial-stage cell and gene therapy company following U.S. FDA approval of ZEVASKYN® on April 28, 2025 for treating wounds in adults and children with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin disease with no cure.
ZEVASKYN® is the first and only FDA-approved autologous cell-based gene therapy for RDEB wounds and is manufactured at Abeona’s cGMP facility in Cleveland, Ohio. As of March 2026, four qualified U.S. treatment centers are activated, and the company has broad commercial and Medicaid coverage plus a permanent J‑code effective January 1, 2026.
The company sold a Rare Pediatric Disease Priority Review Voucher for $155.0 million, strengthening its cash position, and estimates about 750 moderate-to-severe RDEB patients in the U.S. could be eligible for ZEVASKYN®. Abeona is also advancing AAV-based gene therapies for XLRS (ABO‑503), Stargardt disease (ABO‑504), and ADOA (ABO‑505) using its AIM™ capsid platform and has multiple out‑licensing and capsid-licensing deals supporting additional milestone and royalty potential.
Abeona Therapeutics reported its first full year of commercialization in 2025 with a sharp move to profitability driven by a one-time asset sale. Total revenue was $5.8 million, including $2.4 million in net product revenue from ZEVASKYN and $3.4 million in license and other revenues.
The company recorded a loss from operations of $89.4 million as it ramped commercial infrastructure, but net income reached $71.2 million, or $1.34 per basic share, mainly due to a $152.4 million gain from selling a Priority Review Voucher for $155.0 million. Cash, cash equivalents and short-term investments were $191.4 million as of December 31, 2025. ZEVASKYN, approved by the FDA in April 2025, saw its first commercial treatment in December, with additional biopsies and treatments underway in early 2026.